NCT03634007View on ClinicalTrials.gov

Gene Therapy for APOE4 Homozygote of Alzheimer's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 6, 2019

Primary Completion Date

November 7, 2024

Study Completion Date

November 7, 2024

Conditions
Alzheimer DiseaseEarly Onset Alzheimer Disease
Interventions
BIOLOGICAL

LX1001

LX1001 is a serotype rh.10 AAV gene transfer vector expressing the cDNA coding for human APOE2.

Trial Locations (4)

10021

Weill Cornell Medicine, New York

27708

Duke University, Durham

32751

K2 Medical Research, Maitland

32806

PPD- Orlando Research Unit, Orlando

Sponsors

Lead Sponsor

Lexeo Therapeutics
All Listed Sponsors
collaborator

Alzheimer's Drug Discovery Foundation

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

lead

Lexeo Therapeutics

INDUSTRY